NAK MEDICAL LIMITED Filleted Accounts Cover
NAK MEDICAL LIMITED
Company No. 09284080
Information for Filing with The Registrar
31 October 2025
NAK MEDICAL LIMITED Directors Report Registrar
The Director presents his report and the accounts for the year ended 31 October 2025.
Principal activities
The principal activity of the company during the year under review was Providing Specialists Medical Practice Activities..
Director
The Director who served at any time during the year was as follows:
N. Kapse
The above report has been prepared in accordance with the provisions applicable to companies subject to the small companies regime as set out in Part 15 of the Companies Act 2006.
Signed on behalf of the board
N. Kapse
Director
07 July 2026
NAK MEDICAL LIMITED Balance Sheet Registrar
at
31 October 2025
Company No.
09284080
Notes
2025
2024
£
£
Current assets
Cash at bank and in hand
564,028528,612
564,028528,612
Creditors: Amount falling due within one year
5
(19,856)
(28,784)
Net current assets
544,172499,828
Total assets less current liabilities
544,172499,828
Net assets
544,172499,828
Capital and reserves
Called up share capital
22
Profit and loss account
7
544,170499,826
Total equity
544,172499,828
These accounts have been prepared in accordance with the special provisions applicable to companies subject to the small companies regime of the Companies Act 2006.
For the year ended 31 October 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
As permitted by section 444 (5A)of the Companies Act 2006 the directors have not delivered to the Registrar a copy of the company's profit and loss account.
Approved by the board on 07 July 2026 and signed on its behalf by:
N. Kapse
Director
07 July 2026
NAK MEDICAL LIMITED Notes to the Accounts Registrar
for the year ended 31 October 2025
1
General information
NAK MEDICAL LIMITED is a private company limited by shares and incorporated in England and Wales.
Its registered number is: 09284080
Its registered office is:
30 Melrose Gardens
Edgware
Middlesex
HA8 5LN
The accounts have been prepared in accordance and comply with FRS 102 and Section 1A - The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.
2
Accounting policies
Revenue recognition
The Company’s contracts with customers typically include a single performance obligation, being the
delivery of provision of services. Revenue is recognised when that performance obligation is satisfied,
which is when control passes to the customer.
Taxation
Income tax expense represents the sum of the tax currently payable and deferred tax.

The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the profit and loss account because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable temporary differences. Deferred tax assets are generally recognised for all deductible timing differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

Current or deferred tax for the year is recognised in profit or loss, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case, the current and deferred tax is also recognised in other comprehensive income or directly in equity respectively.
Trade and other creditors
Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.
Provisions
Provisions are made where an event has taken place that gives the Company a legal or constructive obligation that probably requires settlement by a transfer of economic benefit, and a reliable estimate can be made of the amount of the obligation.

Provisions are charged as an expense to the profit and loss account in the year that the Company becomes aware of the obligation, and are measured at the best estimate at balance sheet date of the expenditure required to settle the obligation, taking into account relevant risks and uncertainties.

When payments are eventually made, they are charged to the provision carried in the balance sheet.
3
Employees
2025
2024
Number
Number
The average monthly number of employees (including directors) during the year was:
11
4
Taxation
(a) Tax on profit on ordinary activities
2025
2024
The tax charge is made up as follows:
£
£
UK corporation tax
Charge for the period
19,17827,518
Total corporation tax
19,17827,518
Tax on profit on ordinary activities
19,17827,518
(b) Factors affecting the total tax charge for the period
The tax assessed for the year is higher than the standard rate of corporation tax in the UK. The differences are reconciled below:
Higher
2025
2024
19178
£
£
Profit on ordinary activities before tax
86,522117,993
Profit on ordinary activities multiplied by standard rate of corporation tax in the United Kingdom
--
Expenses not deductible for tax purposes
19,17827,518
Tax on profit on ordinary activities
19,17827,518
5
Creditors:
amounts falling due within one year
2025
2024
£
£
Taxes and social security
19,208
27,548
Loans from directors
48637
Accruals and deferred income
600599
19,85628,784
6
Share Capital
Ordinary Share Capital
7
Reserves
Profit and loss account - includes all current and prior period retained profits and losses.
8
Dividends
2025
2024
£
£
Dividends for the period:
Dividends paid in the period
23,000
30,500
23,000
30,500
Dividends by type:
Non-equity preference dividends
--
Equity dividends
23,00030,500
23,000
30,500
NAK MEDICAL LIMITED0928408031 October 202501 November 2024false07 July 2026BTCSoftware AP Solution 2026 14.1.1914.1.19true092840802024-11-012025-10-31092840802025-10-31092840802024-10-3109284080core:WithinOneYear2025-10-3109284080core:WithinOneYear2024-10-3109284080core:ShareCapital2025-10-3109284080core:ShareCapital2024-10-3109284080core:RetainedEarningsAccumulatedLosses2025-10-3109284080core:RetainedEarningsAccumulatedLosses2024-10-3109284080countries:UnitedKingdom2024-11-012025-10-3109284080bus:RegisteredOffice2024-11-012025-10-31092840802023-11-012024-10-3109284080core:RetainedEarningsAccumulatedLosses2024-11-012025-10-3109284080bus:AllOrdinaryShares2024-11-012025-10-31092840802024-11-0109284080bus:SmallEntities2024-11-012025-10-3109284080bus:FullAccounts2024-11-012025-10-3109284080bus:AuditExempt-NoAccountantsReport2024-11-012025-10-3109284080bus:Director12024-11-012025-10-3109284080bus:PrivateLimitedCompanyLtd2024-11-012025-10-31iso4217:GBPxbrli:pure